Latest Breaking News On - Sef kurstjens - Page 1 : comparemela.com

Urovant Sciences GmbH: Urovant Sciences Receives Best in Category Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence

United statesSumitovant biopharmaKenneth petersMaya frutigerAlana darden powellDepartment of urology at beaumont hospitalAmerican urological associationInternational continence societyUrovant sciences gmbCorporate communicationsPelvic health centerUrovant sciencesSumitovant biopharma ltdHead of corporate communicationsCategory prizeOveractive bladder

Urovant Sciences, Inc : The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U S Highlighted in New Survey

Survey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC)

United statesThomas jefferson universitySumitovant biopharmaMaya frutigerAlana darden powellRichard stefanacciJefferson college of population healthUrovant sciences gmbCorporate communicationsUs public healthUrovant sciencesSumitovant biopharma ltdHead of corporate communicationsUrinary incontinence relatedOveractive bladderLong term care residents

The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U S Highlighted in New Survey

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesThomas jefferson universitySumitovant biopharmaMaya frutigerAlana darden powellRichard stefanacciJefferson college of population healthUrovant sciences incUrovant sciences gmbCorporate communicationsUrovant sciencesSumitovant biopharma ltdHead of corporate communicationsUrinary incontinence relatedOveractive bladderLong term care residents

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSumitovant biopharmaSumitomo pharmaMaya frutigerAlana darden powellDavid staskinJeffrey frankelDrug administrationAmerican urological associationUrovant sciences incUrovant sciences gmbSeattle urology research centerCorporate communicationsTufts university school of medicineUs public healthUrovant sciences

Urovant Sciences, Inc : Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium

United statesSumitovant biopharmaSumitomo pharmaMaya frutigerAlana darden powellDavid staskinJeffrey frankelDrug administrationAmerican urological associationUrovant sciences gmbSeattle urology research centerCorporate communicationsTufts university school of medicineUs public healthUrovant sciencesSumitovant biopharma ltd